With the rapid growth of injectable therapies such as GLP-1 drugs, insulin, peptides, and biologics, injection pens have become essential drug delivery devices. As combination products integrating both pharmaceutical and medical device functions, injection pens are subject to strict regulatory oversight worldwide.
Understanding and complying with regulatory requirements is critical for pharmaceutical and biotechnology companies seeking successful product development and market access.
1. Regulatory Classification of Injection Pens
Injection pens are typically classified as combination products or drug-device combination systems, as they combine a medicinal product with a medical device.
Major Regulatory Frameworks:
United States (FDA)
Regulated by the FDA as Combination Products
Governed under 21 CFR Parts 4, 210, 211, and 820
European Union (EMA / MDR)
Regulated under EU MDR (2017/745)
Combined with Medicinal Product Directive (2001/83/EC)
China (NMPA)
Regulated as Medical Devices or Combination Products
Subject to NMPA registration and GMP requirements
Other Markets
Follow ICH, ISO, and regional regulatory frameworks
Correct product classification is the foundation for regulatory approval.
2. Quality Management System (QMS) Requirements
Manufacturers of injection pens must establish comprehensive quality management systems aligned with international standards.
Key Standards:
ISO 13485 – Medical device quality management
GMP – Good Manufacturing Practice
21 CFR Part 820 – FDA Quality System Regulation
ICH Q10 – Pharmaceutical Quality System
These systems ensure traceability, risk control, and consistent product quality.
3. Design Control and Risk Management
Injection pens must follow strict design and development procedures.
Core Requirements:
Design input and output documentation
Verification and validation (V&V)
Human factors engineering (IEC 62366)
Risk management (ISO 14971)
Usability and safety testing
Design history files (DHF) and technical documentation are mandatory for regulatory submission.
4. Performance and Safety Testing
Before market approval, injection pens must undergo extensive testing.
Common Testing Categories:
Dose accuracy and repeatability
Mechanical durability and lifecycle testing
Environmental stability testing
Compatibility with drug formulations
Biocompatibility (ISO 10993)
Sterility and packaging integrity testing
Test data forms a core part of regulatory dossiers.
5. Clinical and Usability Evaluation
Regulators require evidence that injection pens can be safely and effectively used by patients.
Evaluation Methods:
Human factors studies
Simulated use testing
Clinical usability trials
Label comprehension studies
These evaluations reduce the risk of misuse and medication errors.
6. Labeling and Instructions for Use (IFU)
Accurate and compliant labeling is legally required.
Labeling Requirements:
Device identification and traceability
Intended use and indications
Step-by-step usage instructions
Warnings and contraindications
Storage conditions
Disposal instructions
Non-compliant labeling is a common cause of regulatory rejection.
7. Regulatory Submission and Market Approval
Typical Approval Pathways:
United States
510(k), De Novo, or PMA (depending on risk class)
Combination Product Application
European Union
CE Marking under MDR
Notified Body conformity assessment
China
Medical Device Registration
Type testing and clinical evaluation
Each region requires region-specific technical documentation.
8. Post-Market Surveillance and Vigilance
Regulatory compliance continues after product launch.
Key Obligations:
Post-Market Surveillance (PMS)
Adverse Event Reporting
Field Safety Corrective Actions (FSCA)
Periodic Safety Update Reports (PSUR)
Product recall procedures
Effective PMS systems protect both patients and corporate reputation.
9. Intellectual Property and Regulatory Protection
Injection pen manufacturers should also consider:
Patent protection for mechanical design
Software and algorithm protection (for smart pens)
Regulatory data exclusivity
Trade secret management
IP strategy and regulatory planning should be coordinated.
10. Building a Sustainable Compliance Strategy
To succeed in global markets, pharmaceutical and biotechnology companies should:
✔ Integrate regulatory planning in early development
✔ Establish cross-functional compliance teams
✔ Work with qualified device partners
✔ Conduct early regulatory consultations
✔ Maintain complete technical documentation
A proactive compliance strategy reduces development risk and accelerates time-to-market.
Conclusion
Injection pens are highly regulated combination products requiring close attention to legal and regulatory requirements throughout their lifecycle.
By establishing robust quality systems, comprehensive testing programs, and effective regulatory strategies, pharmaceutical and biotechnology companies can ensure market access, patient safety, and long-term commercial success.
Copyright © Shijiazhuang Xinfuda Medical Packaging Co., Ltd. All Rights
MAKE AN ENQUIRY
